| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1177/070674370104600308 |
| P698 | PubMed publication ID | 11320682 |
| P2093 | author name string | S M McCann | |
| S H Kennedy | |||
| R S McIntyre | |||
| P2860 | cites work | The relationship between blood prolactin levels and risk of breast cancer in premenopausal women | Q57658869 |
| Ketoacidosis as a side-effect of clozapine: a case report | Q59221805 | ||
| Body Weight and Mortality among Women | Q22250911 | ||
| Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors | Q28119146 | ||
| m-Chlorophenylpiperazine decreases food intake in a test meal | Q28307494 | ||
| Congenital leptin deficiency is associated with severe early-onset obesity in humans | Q29618702 | ||
| Neuroleptic-induced hyperprolactinemia | Q33586375 | ||
| Weight gain: side effect of atypical neuroleptics? | Q33707031 | ||
| Effects of recombinant leptin therapy in a child with congenital leptin deficiency. | Q33874084 | ||
| Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks | Q34301257 | ||
| Weight gain among schizophrenic patients treated with clozapine | Q35254182 | ||
| Neuronal lipopigment: a marker for cognitive impairment and long-term effects of psychotropic drugs | Q35933865 | ||
| Metabolic fuels and reproduction in female mammals | Q36321920 | ||
| Weight gain associated with neuroleptic medication: a review | Q40371451 | ||
| Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics | Q40851029 | ||
| Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro | Q40956761 | ||
| Weight changes with depot neuroleptic maintenance therapy | Q41717291 | ||
| Hypothalamic sites affecting masticatory neurons in rats | Q42470397 | ||
| Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia | Q42510636 | ||
| Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus | Q43699831 | ||
| Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats | Q44729201 | ||
| Clozapine-induced weight gain: prevalence and clinical relevance | Q45169845 | ||
| Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? | Q47194368 | ||
| Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study | Q47238068 | ||
| Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial | Q47254016 | ||
| Prevalence of attempting weight loss and strategies for controlling weight | Q47255320 | ||
| Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid | Q47261398 | ||
| Mood stabilization and weight loss with topiramate | Q47263744 | ||
| Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months | Q47274430 | ||
| Leptin levels in patients with anorexia nervosa are reduced in the acute stage and elevated upon short-term weight restoration | Q47305899 | ||
| Weight reduction in schizophrenics by molindone | Q47331051 | ||
| Differential effect of clozapine on weight: a controlled study | Q47331289 | ||
| Weight Changes With Schizophrenic Psychosis and Psychotropic Drug Therapy | Q47386655 | ||
| Use of topiramate, a new anti-epileptic as a mood stabilizer | Q48777380 | ||
| Yohimbine impairs P50 auditory sensory gating in normal subjects. | Q50524442 | ||
| Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) | Q52046642 | ||
| A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. | Q52069574 | ||
| Too many chronic mentally disabled patients are too fat. | Q52081902 | ||
| Recent advances in basic obesity research. | Q52173371 | ||
| Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. | Q53589905 | ||
| Molindone in chronic schizophrenia. | Q54192063 | ||
| Serum leptin levels increase rapidly after initiation of clozapine therapy | Q57338243 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | weight gain | Q3403879 |
| P304 | page(s) | 273-281 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Canadian Journal of Psychiatry | Q5030253 |
| P1476 | title | Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities | |
| P478 | volume | 46 |
| Q46766527 | A crossover study on lipid and weight changes associated with olanzapine and risperidone |
| Q43832862 | A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms |
| Q48247071 | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). |
| Q46070377 | Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats |
| Q27323282 | Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance |
| Q35693269 | Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications |
| Q34661499 | Almost all antipsychotics result in weight gain: a meta-analysis |
| Q37725872 | Alterations of Lipid-Lipoprotein and Leptin in Bipolar Disorder Associated with Clinic Process. |
| Q42864443 | Antipsychotic drugs and diabetes. |
| Q35826319 | Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia |
| Q48258866 | Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). |
| Q61458788 | Assessing metabolic syndrome in people with ID (intellectual disabilities) on antipsychotic medication |
| Q46561251 | Assessment of metabolic impairments inducted by atypical antipsychotics among schizophrenic patients |
| Q35793345 | Atypical antipsychotics and diabetes mellitus |
| Q36205791 | Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. |
| Q36302677 | Atypical antipsychotics in psychiatric practice: practical implications for clinical monitoring |
| Q35133099 | Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician. |
| Q35212362 | Behavioural management of antipsychotic-induced weight gain: a review |
| Q41118477 | Blood lactate levels as a biomarker of antipsychotic side effects in patients with schizophrenia |
| Q35100107 | Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate |
| Q38050714 | Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication |
| Q28728401 | Changes in body weight and psychotropic drugs: a systematic synthesis of the literature |
| Q44263522 | Characterization of olanzapine-induced weight gain in rats |
| Q51185707 | Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. |
| Q50124634 | Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents |
| Q35918173 | Desipramine inhibits histamine H1 receptor-induced Ca2+ signaling in rat hypothalamic cells |
| Q50778364 | Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study. |
| Q46735466 | Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia |
| Q44418817 | Effect of Acute Psychotic Stress in Nondiabetic Subjects on β-Cell Function and Insulin Sensitivity |
| Q37257633 | Effectiveness of a psychosocial weight management program for individuals with schizophrenia |
| Q44622757 | Effects of olanzapine on lipid abnormalities in elderly psychotic patients |
| Q47554150 | Effects of primary care clinician beliefs and perceived organizational facilitators on the delivery of preventive care to individuals with mental illnesses. |
| Q48310435 | Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study |
| Q50096809 | Exploring the Relationship Between Body Mass Index and Positive Symptom Severity in Persons at Clinical High Risk for Psychosis |
| Q47201475 | Functional Changes of Orexinergic Reaction to Psychoactive Substances. |
| Q33964839 | H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. |
| Q37147674 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one |
| Q90860747 | Increased risk of type 2 diabetes among the siblings of patients with schizophrenia |
| Q33721019 | Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders |
| Q51901947 | Influence of medication choice and comorbid diabetes: the cost of bipolar disorder in a privately insured US population. |
| Q48404127 | Insights into the structure and function of 5-HT(2) family serotonin receptors reveal novel strategies for therapeutic target development |
| Q36377890 | Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review |
| Q36033305 | Intramuscular olanzapine: a review of its use in the management of acute agitation |
| Q88687824 | Iron overload prevents oxidative damage to rat brain after chlorpromazine administration |
| Q44858920 | Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications |
| Q36258561 | Metabolic side effects of atypical antipsychotics in children: a literature review |
| Q88808771 | Metabolic side effects of atypical antipsychotics in older adults |
| Q37821806 | Mood disorders and obesity: understanding inflammation as a pathophysiological nexus |
| Q44202981 | New-onset diabetes and ketoacidosis with atypical antipsychotics |
| Q47305725 | No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs |
| Q38163397 | Paliperidone extended-release: safety and tolerability from a metabolic profile perspective |
| Q77597822 | Pharmacoepidemiology and drug safety |
| Q80312477 | Pharmacogenetics of antipsychotic-induced weight gain |
| Q35548146 | Pharmacotherapy to limit weight gain caused by antipsychotic use |
| Q36832356 | Phentermine, sibutramine and affective disorders. |
| Q79102815 | Position of the American Dietetic Association: Integration of medical nutrition therapy and pharmacotherapy |
| Q42172035 | Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin |
| Q33519730 | Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration |
| Q40836016 | Prevalence of Antidiabetic and Antilipidemic Medications in Children and Adolescents Treated With Atypical Antipsychotics in a Virginia Medicaid Population |
| Q37479172 | Psychiatric treatment: A risk factor for obesity? |
| Q36836820 | Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings |
| Q45053023 | Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin |
| Q39675765 | Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. |
| Q35612445 | Risperidone in acute and long-term therapy of schizophrenia--a clinical profile |
| Q45147293 | Schizophrenia, diabetes mellitus and antipsychotics |
| Q39353717 | Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies |
| Q37958894 | Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects |
| Q79303671 | The Effect of Antipsychotics on Plasma Lipids |
| Q38777526 | The impact of weight gain associated with atypical antipsychotic use in schizophrenia |
| Q37155311 | The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics |
| Q44103185 | Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study |
| Q34550254 | Treating bipolar disorder. Evidence-based guidelines for family medicine |
| Q35673093 | Treatment of acute mania |
| Q33861601 | Treatment-resistant depression in primary care across Canada |
| Q35102481 | Understanding the new and evolving profile of adverse drug effects in schizophrenia |
| Q35692834 | Use of psychopharmacologic agents in the elderly. |
| Q51537591 | Valproate, bipolar disorder and polycystic ovarian syndrome. |
| Q44612816 | WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics |
| Q44602396 | Weight Change after an Atypical Antipsychotic Switch |
| Q35669815 | Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management |
| Q36230583 | Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies |
| Q89037507 | Which components of specialized early intervention for psychosis do senior providers see as most important? |
| Q81442160 | [How much general medical competency does a psychiatrist need?] |
Search more.